Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors

Zhi Rong Qian, Tingting Li, Monica Ter-Minassian, Juhong Yang, Jennifer A. Chan, Lauren K. Brais, Yohei Masugi, Arunthathi Thiaglingam, Nichole Brooks, Reiko Nishihara, Mireille Bonnemarie, Atsuhiro Masuda, Kentaro Inamura, Sun A. Kim, Kosuke Mima, Yasutaka Sukawa, Ruoxu Dou, Xihong Lin, David C. Christiani, Fabien SchmidlinCharles S. Fuchs, Umar Mahmood, Shuji Ogino, Matthew H. Kulke

Research output: Contribution to journalArticle

26 Citations (Scopus)


OBJECTIVE: Somatostatin receptors (SSTRs), products of gene superfamily SSTR1-5, are commonly expressed in neuroendocrine tumors (NETs). Somatostatin analogs (SSAs) bind to SSTRs and are used as therapeutic agents in patients with advanced NETs. We hypothesized that tumor SSTR expression status would be associated with clinical outcomes in NET. METHODS: Expression of the 5 SSTRs was evaluated by immunohistochemistry, using tissue microarrays comprising 173 primary NETs, 24 matched metastases, and 22 metastatic NETs from 195 patients. Cox proportional hazards regression analysis was used to assess the association of SSTR expression status (high vs low) with clinical outcomes, adjusting for potential confounders. RESULTS: High expression of SSTR2 was associated with longer overall survival (OS) in the cohort overall (multivariate hazard ratio, 0.42; 95% confidence interval, 0.21–0.84; P = 0.013). In a subgroup of patients with metastatic small intestine NET treated with SSAs and evaluable for progression, SSTR2 expression was associated with both longer progression-free survival (PFS) and OS. No associations with PFS or OS were observed with expression of other SSTRs. CONCLUSIONS: Our study demonstrated that expression of SSTR2, but not other SSTRs, is associated with longer OS. In patients treated with SSAs, expression of SSTR2 is associated with longer PFS survival.

Original languageEnglish
Publication statusAccepted/In press - 2016 Sep 12

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Fingerprint Dive into the research topics of 'Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors'. Together they form a unique fingerprint.

  • Cite this

    Qian, Z. R., Li, T., Ter-Minassian, M., Yang, J., Chan, J. A., Brais, L. K., Masugi, Y., Thiaglingam, A., Brooks, N., Nishihara, R., Bonnemarie, M., Masuda, A., Inamura, K., Kim, S. A., Mima, K., Sukawa, Y., Dou, R., Lin, X., Christiani, D. C., ... Kulke, M. H. (Accepted/In press). Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas.